Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Corona SP, et al. Among authors: dester m. Oncotarget. 2020 Jun 9;11(23):2172-2181. doi: 10.18632/oncotarget.27612. eCollection 2020 Jun 9. Oncotarget. 2020. PMID: 32577163 Free PMC article.
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment.
Ianza A, Giudici F, Pinello C, Corona SP, Strina C, Bernocchi O, Bortul M, Milani M, Sirico M, Allevi G, Aguggini S, Cocconi A, Azzini C, Dester M, Cervoni V, Bottini A, Cappelletti M, Generali D. Ianza A, et al. Among authors: dester m. Tumour Biol. 2020 Jun;42(6):1010428320925301. doi: 10.1177/1010428320925301. Tumour Biol. 2020. PMID: 32489146 Free article. Clinical Trial.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Sirico M, et al. Among authors: dester m. Cancers (Basel). 2020 Nov 10;12(11):3314. doi: 10.3390/cancers12113314. Cancers (Basel). 2020. PMID: 33182575 Free PMC article.
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. Roviello G, et al. Among authors: dester m. Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21. Future Oncol. 2016. PMID: 27324108 Clinical Trial.
CDK4/6 inhibitors in HER2-positive breast cancer.
Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D. Corona SP, et al. Among authors: dester m. Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Crit Rev Oncol Hematol. 2017. PMID: 28325261 Review.
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients.
Generali D, Rocca A, Strina C, Milani M, Fiorino E, Cervoni V, Azzini C, Saracino A, Ciliberto I, Ziglioli N, Alberio M, Giudici F, Dester M, Ciani O, Fornaro G, Aguggini S, Dreezen C, Pronin D, Ende S. Generali D, et al. Among authors: dester m. Heliyon. 2024 Oct 26;10(21):e39485. doi: 10.1016/j.heliyon.2024.e39485. eCollection 2024 Nov 15. Heliyon. 2024. PMID: 39553665 Free PMC article.
Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Corona SP, et al. Among authors: dester m. Oncotarget. 2022 Dec 6;13:1307. doi: 10.18632/oncotarget.28317. Oncotarget. 2022. PMID: 36473136 Free PMC article. No abstract available.
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group. Cazzaniga ME, et al. Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13. Breast. 2017. PMID: 28711793